LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Akcijų sąrašas・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.17

Max

0.17

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.5M -37M
Pardavimai	14M 14M
Pelnas, tenkantis vienai akcijai	-0.111
Pelno marža	-262.996
Darbuotojai	142
EBITDA	10M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+4515.38% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-51M 74M
Ankstesnė atidarymo kaina	0.17
Ankstesnė uždarymo kaina	0.17

Naujienos nuotaikos

By Acuity

50%

187 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

0.5207 / 0.7223 Palaikymas ir pasipriešinimas

Sangamo Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-06 23:41; UTC

Uždarbis

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

2026-05-06 21:40; UTC

Uždarbis

Nutrien Logs Higher Profit, Sales Growth in 1Q

2026-05-06 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-05-06 23:34; UTC

Rinkos pokalbiai

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

2026-05-06 23:12; UTC

Uždarbis

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

2026-05-06 23:11; UTC

Uždarbis

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

2026-05-06 23:07; UTC

Uždarbis

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

2026-05-06 23:05; UTC

Uždarbis

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

2026-05-06 23:04; UTC

Uždarbis

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-05-06 22:25; UTC

Rinkos pokalbiai

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

2026-05-06 22:05; UTC

Rinkos pokalbiai

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

2026-05-06 21:58; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:47; UTC

Rinkos pokalbiai

Uždarbis

Costco Posts 13% Sales Growth in April -- Market Talk

2026-05-06 21:46; UTC

Uždarbis

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

2026-05-06 21:40; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:35; UTC

Rinkos pokalbiai

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

2026-05-06 21:32; UTC

Karštos akcijos

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

2026-05-06 21:29; UTC

Uždarbis

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sangamo Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

4515.38% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 4515.38%

Aukščiausias 10 USD

Žemiausias 2 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sangamo Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Sangamo Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.5207 / 0.7223Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

187 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.